LIVESTRONG To Fund Support Group At James Cancer Hospital

June 09, 2011

COLUMBUS, Ohio – The LIVESTRONG Community Impact Project is funding a post-treatment support program for cancer survivors at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James).

The project, created by LIVESTRONG, the organization founded by cancer survivor and champion cyclist Lance Armstrong, is bringing proven cancer support programs to 86 communities across the United States.

The award recipients are among 200 qualified hospitals, cancer centers, university students and community organizations selected to participate in an online voting campaign. During a three-week period in May, more than 340,000 votes were cast, with OSUCCC – James among the 93 finalists.

"We are proud to be named as a LIVESTRONG Community Impact Project award recipient," said Dr. Michael Caligiuri, director of Ohio State's Comprehensive Cancer Center and CEO of the James Cancer Hospital and Solove Research Institute. "This award will directly impact our ability to support those in our community who are affected by cancer. We appreciate those who voted in support of this program. Together, we're making a difference in the lives of cancer survivors and their families."

The award will fund Cancer Transitions: Moving Beyond Treatment, which is designed to help people with cancer in the transitional period after treatment is over. The program incorporates support groups, education, nutrition and physical exercise, along with addressing other medical management, psychosocial and quality of life issues.

While every survivor can benefit from this program, OSUCCC – James will target two underserved populations: young adults and minorities who frequently do not seek supportive services.

"By investing in these bold and innovative cancer support programs, LIVESTRONG is providing inspiration and empowerment to area residents so they can band together as a community to face cancer head-on," said Doug Ulman, LIVESTRONG president and CEO. "We are grateful to each and every person who voted for making their voices heard and improving access to care for those affected by cancer."

Since its inception in 1997, LIVESTRONG has invested nearly $70 million in community-centered organizations.

The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute ( is one of only 40 Comprehensive Cancer Centers in the United States designated by the National Cancer Institute. Ranked by U.S. News & World Report among the top cancer hospitals in the nation, The James is the 205-bed adult patient-care component of the cancer program at The Ohio State University. The OSUCCC – James is one of only seven centers in the country funded by the NCI to conduct both phase I and phase II clinical trials.

# # #

Contact: Eileen Scahill, Medical Center Public Affairs and Media Relations, 614-293-3737, or

Contact Media Staff

Amanda Harper

Director of Media Relations

614-685-5420 (direct)

614-293-3737 (main)

Media staff are available by calling 614-293-3737 Monday through Friday between 8 a.m. and 5 p.m.


If after hours, please call 614-293-8000 (ask the operator to page the hospital administrative manager).

Latest News

Ohio State, ORIEN Could Play Role in Vice President's Cancer Moonshot Initiative

ORIEN, a network formed by Ohio State and Moffitt Cancer Center, could play an important role in the White House Cancer Moonshot initiative by facilitating the sharing of important data.

Ohio State: An Exceptional Comprehensive Cancer Center Helping Cancer Patients

Director of the OSUCCC Dr. Michael Caligiuri discusses the importance of being an NCI-designated comprehensive cancer center, where research flourishes and the best scientists and physicians want to work.

A Fireside Chat with The James CEO Dr. Michael Caligiuri

Dr. Caligiuri hosts a chat where he talked about the “exceptional” rating The James recently received from the NCI, advances in immunology & how ORIEN could play a role in the cancer “moonshot” program.